UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

                        Date of Report: November 23, 2004

                                 CYTOMEDIX, INC.
             (Exact name of registrant as it appears in its charter)

          Delaware                     0-28443               23-3011702
(State or other jurisdiction   (Commission File Number) (IRS Employer
      of incorporation)                                   Identification No.)

                         416 Hungerford Drive, Suite 330
                            Rockville, Maryland 20850
              (Address of principal executive offices and zip code)

                                 (301) 251-2815
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))




Section 5--Corporate Governance and Management

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers

(d) On November 23, 2004, Mr. Arun K. Deva accepted an appointment to fill a
vacancy on the Cytomedix, Inc. board of directors. Cytomedix issued the attached
press release announcing that Mr. Deva had accepted the appointment made by the
Cytomedix board of directors. The press release is filed as Exhibit 99.1 and
incorporated herein by reference.


Section 9--Financial Statements and Exhibits

Item 9.01  Financial Statements and Exhibits.

(c) Exhibits. The following Exhibit is furnished with this Current Report on
Form 8-K:

Exhibit No.       Description
- -----------       -----------
Exhibit 99.1      Press Release of Cytomedix, Inc., dated November 23, 2004.


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           CYTOMEDIX, INC.

                                           By: /s/ Kshitij Mohan
                                              ---------------------------------
                                                   Kshitij Mohan
                                                   Chief Executive Officer


Date:  November 23, 2004